Study finds nearly half of payers believe innovative contracts can lead to lower patient out-of-pocket costs

According to arecent survey by Verpora that will be presented this week atISPOR, nearly half of U.S. payers surveyed expressed a belief that wider implementation ofinnovative contracts could lead to lower patient out-of-pocket costs across small molecule, biologic, cell and gene therapies. This echoes the support biopharmaceutical companies have for these innovative contracts, and recent studies that demonstrate the potential impact value-based approaches can have on improving patient health outcomes, decreasing payer costs andlowering patient out-of-pocket spending. 
Source: The Catalyst - Category: Pharmaceuticals Authors: Tags: Out-of-Pocket Costs The Value Collaborative Value-Based Contracting Source Type: news